查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
近距離放射治療設備市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)
市場調查報告書
商品編碼
1190135

近距離放射治療設備市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Brachytherapy Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 112 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計近距離放射治療設備市場在預測期內（2022 年至 2027 年）的複合年增長率為 5.5%。

COVID-19 大流行影響了全球醫療保健系統，也對近距離治療設備市場產生了重大影響。 根據發表在 Cancer Connect 2020 上的一篇文章，共有 7 名本應接受近距離放射治療的前列腺癌患者在四家醫院接受了治療。 然而，只有 3 名 (43%) 患者能夠接受近距離放射治療。 根據 2021 年 1 月發表的題為“大流行期間 COVID-19 對近距離放射治療的影響”的研究。 在 Rutgers-Robert Wood Johnson Barnabas Health Multisite Experience (Advancements in Radiation Oncology) 中，6 名患者選擇了 EBRT，隨後對不利的中高風險疾病進行了近距離放療，並發現在大流行期間，4 名患者接受了 EBRT 治療，有或沒有單獨的雄激素剝奪療法 (ADT)，因為擇期手術被取消。 儘管衛生系統在大流行期間面臨挑戰，但大多數癌症患者能夠安全地接受治療，只有輕微的延誤或中斷。 因此，由於 COVID-19 的限制，它受到了很大的影響。 然而，隨著心臟手術的增加，對近距離治療設備的需求有望推動市場增長。

近距離放射治療設備通常用於有效治療婦科、前列腺和乳腺癌等癌症，從而增加了全世界的癌症負擔。，預計將對調查市場的增長產生重大影響。 例如，根據國際癌症研究機構（IARC）的數據，2020 年全球癌症發病率估計約為 1930 萬，預計到 2030 年將增至 2460 萬。 此外，乳腺癌是最常見的癌症之一，2020 年估計有 226 萬新病例。 近距離放射治療是一種利用體內放射性來切除和殺死體內靶點內或附近的癌細胞和腫瘤細胞的治療方法。 它還與化學療法、手術和外部放射療法結合使用。 因此，預計在預測期內，癌症患病率的增加將推動近距離放射治療市場的增長。

此外，2021 年 10 月，愛丁堡癌症中心宣布將為侵襲性前列腺癌提供高劑量率近距離放射治療。 該中心是蘇格蘭首批提供 HDR-BT 治療前列腺癌的癌症治療中心之一。 因此，這些努力有望進一步對研究目標市場的增長產生積極影響。

根據國際原子能機構 (IAEA) 放射治療中心名錄 (DIRAC)，到 2020 年，全球放射治療中心將安裝約 3,300 套近距離放射治療系統，其中約 60% 的癌症患者發生在低危人群中- 和中等收入國家 (LMIC)。 在這些國家，80% 的患者由於獲得先進技術產品的機會有限而未接受治療。 雖然 60-80% 的放射治療需求在歐洲國家得到滿足，但在低收入和中等收入國家 (LMIC) 僅滿足 3-4%。 其他因素，如政府加大力度提高微創手術的意識和技術進步，預計將在預測期內推動近距離治療設備市場。 因此，由於上述因素，近距離放射治療市場有望在預測期內增長。 然而，缺乏熟練的放射科醫生和先進的放射治療設施、報銷問題等是預測期內限制市場增長的主要因素。

主要市場趨勢

乳腺癌領域預計在預測期內將錄得顯著增長

按應用劃分，該市場分為婦科癌症、前列腺癌、乳腺癌等，其中與其他癌症類型相比，乳腺癌細分市場有望實現顯著增長。 這主要是由於全球範圍內乳腺癌患病率的增加。 例如，國際癌症研究機構 (IARC) 2020 年報告提供的估計表明，到 2020 年，全球將診斷出約 230 萬新髮乳腺癌病例，超過任何其他形式的癌症。到 2040 年，乳腺癌的發病率預計乳腺癌將達到約300萬例，有望提振近距離治療市場。

乳房內近距離放射治療也是乳腺癌女性最常見的近距離放射治療類型。 根據AIARC 2020報告，亞洲地區將是多年來乳腺癌患病率最高的地區之一，其次是歐洲和非洲地區。 因此，乳腺癌的高負擔有望增加對乳腺癌治療的需求，從而促進該細分市場的增長。 此外，旨在提高微創手術意識和技術進步的政府舉措不斷增加，也促進了近距離放射治療設備市場的增長。 例如，2021 年 11 月，位於印度恰蒂斯加爾邦的全印度醫學科學研究所 (AIIMS) 開始在賴布爾區對包括乳腺癌在內的癌症患者進行近距離放射治療。 因此，由於上述因素，預計乳腺癌部分在預測期內將佔據近距離治療市場的很大份額。

北美主導市場，預計在預測期內也會如此

由於癌症發病率上升和新技術的早期採用，北美在市場上佔據主導地位。 由於患者人數眾多和基礎設施豐富，美國占據了北美地區的大部分市場。 例如，根據 IARC 2020 報告，北美地區約有 260 萬新發癌症病例，預計到 2040 年癌症發病率將增至 350 萬。 因此，對近距離放射治療的需求增加預計將推動該地區的市場增長。

此外，乳腺癌是美國主要的癌症類型之一。 根據美國癌症協會 2022 年 1 月的更新，美國大約每 8 名女性中就有 1 名（約 13%）會在其一生中患上浸潤性乳腺癌。 根據同一份報告，到 2022 年，估計美國女性將診斷出 287,850 例浸潤性乳腺癌新病例和 51,400 例原位乳腺癌新病例。 據同一消息來源稱，預計到 2022 年，男性將診斷出約 2,710 例浸潤性乳腺癌新病例。 男性一生患乳腺癌的風險約為 833 分之一。 此外，2021 年 10 月，Susan G. Komen 撥款 150 萬美元用於新的研究項目，以調查三個以轉移性乳腺癌 (MBC) 為重點的獨特領域。 該贈款是 Komen、DUnited Kingdom 癌症研究所和北卡羅來納大學 Lineberger 綜合癌症中心之間創新和首次合作的一部分，即 Susan G. Komen 轉移性乳腺癌合作研究計劃。 因此，由於上述因素，預計市場在預測期內將出現顯著增長。

競爭格局

近距離放射治療設備市場競爭激烈，由多家大型企業組成。 這些主要參與者中的大多數都享有全球影響力，並在新興市場面臨激烈的競爭。 近距離放射治療設備市場的主要參與者包括 Argon Medical Devices、Becton、Dickinson and Company、Carl Zeiss Meditec AG、Eckert &Ziegler BEBIG S.A.、Elekta AB、iCAD Inc、Isoray Inc、Theragenics Corporation、Varian Medical Systems Inc。我們提供這些產品

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 癌症發病率增加
    • 政府提高認識的努力變得更加積極
    • 微創手術的技術進步
  • 市場製約因素
    • 缺乏熟練的放射科醫生和先進的放射治療設備
    • 保險報銷問題
  • 五力分析分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 按技術
    • 高劑量率近距離放射治療裝置
    • 低劑量率近距離放射治療裝置
  • 通過申請
    • 婦科癌症
    • 前列腺癌
    • 乳腺癌
    • 其他
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Argon Medical Devices, Inc.
    • Becton, Dickinson and Company
    • Carl Zeiss Meditec AG
    • Eckert & Ziegler BEBIG S.A.
    • Elekta AB
    • iCAD Inc
    • Isoray Inc
    • Theragenics Corporation
    • Varian Medical Systems Inc
    • CIVCO Medical Solutions
    • Theragenics Corporation
    • Argon Medical

第7章 市場機會今後動向

簡介目錄
Product Code: 67420

The brachytherapy devices market is projected to register a CAGR of 5.5% during the forecast period (2022-2027).

The COVID-19 pandemic has affected the healthcare systems globally and also has had a significant impact on the Brachytherapy devices market. As per the article published in Cancer Connect 2020, A total of 7 patients with prostate cancer who were scheduled to receive brachytherapy were treated across the 4 hospitals. However, only 3 patients (43%) were able to undergo brachytherapy. As per the study published in January 2021, titled "The Impact of COVID-19 on Brachytherapy During the Pandemic: A Rutgers-Robert Wood Johnson Barnabas Health Multisite Experience", by advances in radiation oncology, six patients elected to undergo EBRT followed by a brachytherapy boost for unfavorable intermediate- and high-risk diseases and since elective surgeries were canceled within the system during the pandemic, 4 patients were treated with EBRT with or without androgen deprivation therapy (ADT) only. Despite the challenges, the health care system faced during the pandemic, most patients with cancer were safely treated with minor treatment delays and interruptions. Thus, due to the COVID-19 imposed restrictions, the was significantly impacted. However, with the increase in cardiac surgeries, the demand for brachytherapy devices is expected to boost the growth of the market.

Brachytherapy devices are commonly used for effectively treating gynecologic, prostate, breast, and other types of cancer and thus increasing the burden of cancer around the world is expected to have a significant impact on the growth of the studied market. For instance, according to the International Agency for Research on Cancer (IARC), the global incidence of cancer in 2020 was estimated to be around 19.3 million, which is expected to increase to 24.6 million by the year 2030. Furthermore, breast cancer is among the most common cancer, with around 2.26 million new cases in 2020. Brachytherapy is related to the implementation of radioactivity within the body, to ablate or kill cancer or tumor cells within, or near the target area in the body. It is also used in combination with chemotherapy, surgery, or external radiation therapy. Thus, the increasing prevalence of cancer is expected to fuel growth in the brachytherapy market over the forecast period.

Moreover, in October 2021, Edinburgh Cancer Center published that it would be offering a high dose rate of brachytherapy for the treatment of aggressive prostate cancer. It is one of the first cancer care centers in Scotland to offer HDR-BT for treating prostate cancer. Hence, initiatives like this are further expected to have a positive impact on the growth of the studied market.

According to the International Atomic Energy Agency's (IAEA) Directory of Radiotherapy Centers (DIRAC), as of 2020, there are around 3,300 brachytherapy systems installed across radiation therapy centers worldwide, of which around 60% of the cancer cases occur in low and low middle-income countries (LMICs). 80% of patients in these countries lack access to treatment as they have limited access to technologically advanced products. In Low and Low Middle-Income Countries (LMICs), only 3-4% of the radiotherapy needs are met as opposed to 60-80% in the European countries. Other factors, such as rising government initiatives to increase awareness and technological advancements in minimally invasive surgical procedures are expected to drive the brachytherapy devices market in the forecast period. Therefore, due to the aforementioned factors, the brachytherapy market is expected to grow over the forecast period. However, the lack of skilled radiologists and advanced radiotherapy facilities, and reimbursement issues are among the major barrier to the growth of this market over the forecast period.

Key Market Trends

Breast Cancer Segment is Expected to Register a Significant Growth Over the Forecast Period

By Application, the market has been segmented into gynecologic cancer, prostate cancer, breast cancer, and others, of which the breast cancer segment is expected to register significant growth as compared to other cancer types. This is majorly attributed to the increasing prevalence of breast cancer across the world. For instance, as per estimates provided by the International Agency for Research on Cancer (IARC) 2020 report, in 2020, about 2.3 million new cases of breast cancer were diagnosed all over the world, more than any other form of cancer and by 2040, the incidence of breast cancer is projected to reach about 3 million cases and thus, with the rising burden of breast cancer, the demand for effective and advanced therapeutics is expected to increase that is expected to boost brachytherapy market over the forecast period.

In addition, intracavitary brachytherapy is one of the most common types of brachytherapy for women with breast cancer and as per the AIARC 2020 report, the Asia region was expected to have one of the highest prevalence of breast cancer over the years followed by Europe and Africa region. Therefore, the high burden of breast cancer is expected to increase the demand for breast cancer treatment, thereby contributing to the market segment growth. Further, rising government initiatives to increase awareness and technological advancements in minimally invasive surgical procedures also contribute to the growth of the brachytherapy devices market. For instance, in November 2021, the All India Institute of Medical Sciences (AIIMS) of Chhattisgarh state India started brachytherapy for cancer patients including breast cancer in the Raipur district. Therefore, owing to the above-mentioned factors, the breast cancer segment is expected to have a significant market share in the brachytherapy market over the forecast period.

North America Dominates the Market and Expected to do the Same Over the Forecast Period

North America dominates the market owing to the increasing incidences of cancer and early adoption of new technologies. United States holds the majority of the market in the North American region due to its high patient pool and well-developed infrastructure. For instance, according to the IARC 2020 report, approximately 2.6 million new cases of cancer were recorded in the North American region and by 2040, the incidence of cancer is expected to increase to 3.5 million cancer cases. Hence, the demand for brachytherapy is expected to increase in the region which is anticipated to drive market growth.

Moreover, in United States, breast cancer is one of the leading cancer types. According to the January 2022 update by the American Cancer Society, about 1 in 8 United States women (about 13%) will develop invasive breast cancer throughout their lifetime. The same source reports that in 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in United States, along with 51,400 new cases of non-invasive (in situ) breast cancer. As per the same source, about 2,710 new cases of invasive breast cancer are expected to be diagnosed in men in 2022. A man's lifetime risk of breast cancer is about 1 in 833. Furthermore, in October 2021, Susan G. Komen awarded USD 1.5 million for three new research projects that examine three unique areas focused on metastatic breast cancer (MBC). The grants are part of the Susan G. Komen Metastatic Breast Cancer Collaborative Research Initiative, an innovative, first-of-its-kind collaboration between Komen, Duke Cancer Institute, and the University of North Carolina Lineberger Comprehensive Cancer Center. Thus, due to the above-mentioned factors, the market is expected to witness significant growth during the forecast period.

Competitive Landscape

The Brachytherapy Devices market is fairly competitive and consists of several major players. Most of these major players enjoy a global presence, and they are facing intense competition in emerging economies. The major players in the brachytherapy devices market includes Argon Medical Devices, Becton, Dickinson and Company, Carl Zeiss Meditec AG, Eckert & Ziegler BEBIG S.A., Elekta AB, iCAD Inc., Isoray Inc., Theragenics Corporation, and Varian Medical Systems Inc., which provides these products across the globe.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Cancer
    • 4.2.2 Rising Government Initiatives to Increase Awareness
    • 4.2.3 Technological Advancements in Minimally Invasive Surgical Procedures
  • 4.3 Market Restraints
    • 4.3.1 Lack of Skilled Radiologists and Advanced Radiotherapy Facilities
    • 4.3.2 Reimbursement Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Technique
    • 5.1.1 High Dose Rate Brachytherapy Devices
    • 5.1.2 Low Dose Rate Brachytherapy Devices
  • 5.2 By Application
    • 5.2.1 Gynecologic Cancer
    • 5.2.2 Prostrate Cancer
    • 5.2.3 Breast Cancer
    • 5.2.4 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Argon Medical Devices, Inc.
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 Carl Zeiss Meditec AG
    • 6.1.4 Eckert & Ziegler BEBIG S.A.
    • 6.1.5 Elekta AB
    • 6.1.6 iCAD Inc
    • 6.1.7 Isoray Inc
    • 6.1.8 Theragenics Corporation
    • 6.1.9 Varian Medical Systems Inc
    • 6.1.10 CIVCO Medical Solutions
    • 6.1.11 Theragenics Corporation
    • 6.1.12 Argon Medical

7 MARKET OPPORTUNITIES AND FUTURE TRENDS